Obesity Medicine Association Conference Apr 10–12 2026

Obesity Medicine Association Conference 2026 to Spotlight Clinical Innovation and Market Shifts in San Diego

The Obesity Medicine Association Conference, scheduled for April 10–12, 2026, will convene healthcare professionals, researchers, and industry stakeholders at the Manchester Grand Hyatt San Diego in California. Organized by the Obesity Medicine Association (OMA), the annual conference serves as a central forum for advancing clinical obesity treatment, reviewing emerging therapies, and examining the rapidly evolving business landscape of obesity care.

Held at 1 Market Place, San Diego, CA 92101, the three-day event is expected to draw physicians, nurse practitioners, physician assistants, dietitians, behavioral health professionals, and healthcare executives from across the United States and internationally. The conference details and registration information are available through the official OMA website at https://obesitymedicine.org/education/annual-conference/.

A Clinical and Scientific Hub for Obesity Care

The Obesity Medicine Association Conference is recognized as a leading educational gathering dedicated exclusively to obesity medicine. The meeting focuses on evidence-based treatment strategies, clinical guidelines, metabolic research, and practical approaches to managing obesity as a chronic disease.

Attendees typically include board-certified obesity medicine physicians and clinicians pursuing certification, as well as allied health professionals involved in multidisciplinary care. The program traditionally features:

Evidence-Based Education and Certification Support

The conference agenda emphasizes continuing medical education (CME), with sessions designed to support clinicians preparing for the American Board of Obesity Medicine (ABOM) certification exam. Topics commonly addressed include:

– Pharmacological management of obesity
– Nutritional and behavioral interventions
– Bariatric surgery integration
– Management of obesity-related comorbidities such as type 2 diabetes, cardiovascular disease, and metabolic syndrome
– Pediatric and adolescent obesity treatment

Given the increasing recognition of obesity as a complex, chronic disease, the event provides a structured environment for translating research into clinical practice.

Multidisciplinary Care Models

A central theme of recent OMA conferences has been the importance of team-based care. With obesity treatment often requiring coordinated support across primary care, endocrinology, cardiology, psychology, and nutrition services, the conference highlights scalable care models and integrated health system approaches.

Industry Context: A Rapidly Expanding Obesity Treatment Market

The 2026 conference takes place against the backdrop of unprecedented growth in the global obesity treatment market. The rise of GLP-1 receptor agonists and other advanced anti-obesity medications has transformed both clinical practice and pharmaceutical investment strategies.

In the United States, obesity prevalence continues to exceed 40% among adults, according to federal health data. This sustained demand for treatment has catalyzed:

– Significant R&D investment from pharmaceutical manufacturers
– Expansion of digital weight management platforms
– Increased payer scrutiny and evolving reimbursement policies
– Entry of new telehealth-driven obesity care providers

The Obesity Medicine Association Conference functions as a key intersection between clinical science and commercial innovation, where healthcare providers engage directly with pharmaceutical companies, medical device manufacturers, digital health firms, and nutrition product developers.

Exhibitors and Commercial Participation

While specific exhibitor figures for the 2026 edition have not yet been publicly detailed, OMA conferences traditionally feature a substantial exhibition hall. Exhibitors typically represent sectors such as:

– Prescription obesity pharmacotherapy
– Nutraceuticals and medical-grade nutrition products
– Remote patient monitoring technologies
– Electronic health record integration tools
– Bariatric surgical devices and support services

The exhibit floor serves as a strategic marketplace for companies seeking to connect with prescribing clinicians and decision-makers in obesity treatment. For pharmaceutical firms, in particular, the event provides an opportunity to present clinical data, discuss real-world outcomes, and engage with specialists at the forefront of metabolic care.

Economic Impact for San Diego

Hosting the Obesity Medicine Association Conference at the Manchester Grand Hyatt San Diego underscores the city’s position as a major convention destination. The waterfront venue, located in downtown San Diego, is one of the largest hotel and conference properties on the West Coast.

Medical conferences contribute significantly to local economies through hotel occupancy, dining, transportation, and ancillary tourism spending. With attendees traveling nationally and internationally, the April 2026 event is expected to generate measurable economic activity for the San Diego hospitality sector.

California’s broader life sciences ecosystem also provides strategic relevance. The state is home to numerous biotechnology firms, pharmaceutical companies, and research institutions focused on metabolic disease, making San Diego a logical setting for a high-level obesity medicine gathering.

Strategic Importance for Healthcare Systems and Payers

Beyond clinical education, the Obesity Medicine Association Conference reflects shifting policy and reimbursement dynamics. As anti-obesity medications gain wider adoption, insurers and employers are reevaluating coverage strategies due to cost implications and long-term outcome projections.

Healthcare systems are increasingly building dedicated obesity medicine programs to address demand while managing downstream complications such as diabetes, cardiovascular disease, and orthopedic conditions. Conference discussions often address:

– Cost-effectiveness analyses of pharmacotherapy
– Long-term maintenance strategies
– Employer-sponsored weight management benefits
– Regulatory developments affecting drug approvals and labeling

For hospital administrators and payer representatives, the event offers insight into how obesity treatment may influence overall healthcare expenditure and population health metrics.

Research, Data, and Future Directions

The 2026 conference is also expected to showcase emerging research in metabolic science, including studies on combination therapies, precision medicine approaches, and novel hormonal targets. With obesity increasingly understood as a biologically complex disease influenced by genetics, environment, and neuroendocrine pathways, research presented at OMA meetings often shapes clinical practice guidelines.

In addition, digital therapeutics and artificial intelligence-driven patient management tools are gaining traction. As healthcare systems seek scalable solutions, data analytics and remote monitoring platforms are becoming integral components of obesity care delivery.

A Defining Moment for Obesity Medicine

The Obesity Medicine Association Conference Apr 10–12 2026 arrives at a pivotal moment for the field. Public awareness of obesity as a medical condition—rather than solely a lifestyle issue—continues to grow. Simultaneously, pharmaceutical innovation has redefined treatment expectations, raising both optimism and questions about long-term sustainability.

By convening clinicians, researchers, and industry leaders in San Diego, the conference serves not only as an educational platform but also as a strategic forum for shaping the next phase of obesity medicine. As the market expands and policy frameworks evolve, the discussions and collaborations formed at the Manchester Grand Hyatt are likely to influence clinical standards and commercial strategies well beyond 2026.